Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email email@example.com.
Check back regularly for news, coverage, and announcements about MAVA.
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting, has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $26.0 million and completed a private placement for $1.0 million of Cerulean common stock with Hercules.
Trevi Therapeutics, Inc., a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender.
Welltok, developer of the CafeWell Health Optimization Platform, officially closed its most recent funding round of $37 million.
Trevi Therapeutics has secured a $15 million senior loan from Solar Capital and Square 1 Bank.
Surface Oncology has secured $35 million in Series A funding.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding.
Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.
NanoLumens, the world's leader for visualization solutions in any size, shape or curvature, today announced it has secured $13.3-million in new financing from an offering of debt and securities.
ThermiAesthetics, a fast growing, privately held aesthetic technology company, announced today that it has secured $9,000,000 of debt financing from Cypress Growth Capital and Silicon Valley Bank.
McLean-based BigTeams announced Monday morning both a Series B funding round of $5 million and the acquisition of software provider Schedule Star from Gannett.